Clinical implementation of routine screening for fetal trisomies in the UKNHS: cell‐free DNA test contingent on results from first‐trimester combined test
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objectives: Cell‐free DNA (cfDNA) analysis of maternal blood for detection of trisomies 21, 18 and 13 is superior to other methods of screening but is expensive. One strategy to maximize performance at reduced cost is to offer cfDNA testing contingent on the results of the first‐trimester combined test that is used currently. The objectives of this study were to report the feasibility of implementing such screening, to examine the factors affecting patient decisions concerning their options for screening and decisions on the management of affected pregnancies and to report the prenatal diagnosis of fetal trisomies and outcome of affected pregnancies following the introduction of contingent screening. Methods: We examined routine clinical implementation of contingent screening in 11 692 singleton pregnancies in two National Health Service (NHS) hospitals in the UK. Women with a risk ≥ 1 in 100 (high‐risk group) were offered options of invasive testing, cfDNA testing or no further testing, and those with a risk between 1 in 101 and 1 in 2500 (intermediate‐risk group) were offered cfDNA testing or no further testing. The trisomic status of the pregnancies was determined by prenatal or postnatal karyotyping or by examination of the neonates. Results: In the study population of 11 692 pregnancies, there were 47 cases of trisomy 21 and 28 of trisomies 18 or 13. Screening with the combined test followed by invasive testing for all patients in the high‐risk group potentially could have detected 87% of trisomy 21 and 93% of trisomies 18 or 13, at a false‐positive rate of 3.4%; the respective values for cfDNA testing in the high‐ and intermediate‐risk groups were 98%, 82% and 0.25%. However, in the high‐risk group, 38% of women chose invasive testing and 60% chose cfDNA testing; in the intermediate‐risk group 92% opted for cfDNA testing. A prenatal diagnosis was made in 43 (91.5%) pregnancies with trisomy 21 and all pregnancies with trisomies 18 or 13. In many affected pregnancies the parents chose to avoid testing or termination and 32% of pregnancies with trisomy 21 resulted in live births. Conclusions: Screening for fetal trisomies by cfDNA analysis of maternal blood, contingent on the results of the combined test, can be implemented easily in routine clinical practice. In the high‐risk group from the combined test, most but not all women chose cfDNA testing rather than invasive testing. Performance of screening for trisomy 21 was superior by the cfDNA test than by the combined test. However, prenatal detection of trisomies and pregnancy outcome depend not only on performance of screening tests but also on parental choice. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell-free DNA Analysis for Noninvasive Examination of Trisomy
Norton, M. E., Jacobsson, B., Swamy, G. K., Laurent, L. C., Ranzini, A. C., Brar, H., Tomlinson, M. W., Pereira, L., Spitz, J. L., Hollemon, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407349 · Cited by 817
Cited by
Analysis of cell-free DNA in maternal blood in screening for aneuploidies: Updated meta-analysis
Gil, M. M., Accurti, V., Santacruz, B., Plana, M. N., & Nicolaides, K. H. (2017) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.17484 · Cited by 683
Self-citationSyngelaki, A., Hammami, A., Bower, S., Zidere, V., Akolekar, R., & Nicolaides, K. H. (2019) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.20844 · Cited by 350
Self-citationAdvanced maternal age and adverse pregnancy outcomes
Frick, A. P. (2021) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2020.07.005 · Cited by 304
Screening for trisomies by cell-free DNA testing of maternal blood: Consequences of a failed result
Revello, R., Sarno, L., Ispas, A., Akolekar, R., & Nicolaides, K. H. (2016) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.15851 · Cited by 157
Self-citationChitty, L. S., Wright, D., Hill, M., Verhoef, T. I., Daley, R., Lewis, C., Mason, S., McKay, F., Jenkins, L., Howarth, A., et al. (2016) · BMJ · doi:10.1136/bmj.i3426 · Cited by 149
Metadata
- Authors
- Gil, M. M., Revello, R., Poon, L. C., Akolekar, R., & Nicolaides, K. H.
- Venue
- Ultrasound in Obstetrics & Gynecology
- Publisher
- Wiley
- Published
- 2015-10-26
- Volume
- 47
- Issue
- 1
- Pages
- 45-52
- ISSN
- 0960-7692 (ISSN-L)
- 1469-0705
- OpenAlex
- W1935149375
- Cited by
- 124
- References
- 1
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.